ACW
Actinogen Medical Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
4
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
📈 Performance
Price History
0.00%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.05
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ACW
4
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in ACW
898 days
ACW investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
14%
50k - 100k
29%
Less than 50k
57%
👶 Age of investors
18 - 25
50%
26 - 34
25%
35 - 90
25%
🙋 Legal gender of investors
Female
50%
Male
50%
Pearlers who invest in ACW also invest in...
CRYP.AX was created on 2021-11-02 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. CRYP.AX aims to track the performance of an Index (before fees and expenses) that provides exposure to global companies at the forefront of the crypto economy.
📊 Share price
$2.75 AUD
Pilbara Minerals Ltd. engages in the exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 446 full-time employees. The company went IPO on 2007-09-19. The firm is primarily engaged in the exploration, development, and mining of minerals in Australia. Its 100% owned Pilgangoora hard-rock lithium operation is located approximately 120 kilometers (kms) from Port Hedland in Western Australia’s resource-rich Pilbara region. The operation consists of two processing plants: the Pilgan Plant, located on the northern side of the Pilgangoora area and produces spodumene and tantalite concentrates, and the Ngungaju Plant is located to the south produces spodumene concentrate. The company owns 70% of the Mt Francisco project, which is located 50 km south-west of the Pilgangoora Project and hosts the large occurrence of outcropping pegmatites located nearby to Port Hedland. The company is also pursuing a proposed downstream joint venture (JV) for the development of an approximately 43,000 tons per annum lithium carbonate equivalent (LCE) lithium chemical conversion facility in South Korea.
📊 Share price
$4.67 AUD
NULL RESOURCES
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
📊 Share price
$57.36 AUD
NULL GLOBAL
NULL SMART BETA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
Magnis Energy Technologies Ltd. is engaged in the business of exploring, developing and mining natural flake graphite and manufacturing lithium-ion battey. The company is headquartered in Sydney, New South Wales and currently employs 7 full-time employees. The company went IPO on 2005-10-25. The firm supports and accelerates the adoption of electric vehicles and renewable energy storage critical for the green energy transition. The firm's subsidiary, Imperium3 New York, Inc (iM3NY), operates a Gigawatt scale Lithium-ion battery manufacturing project in Endicott, New York. The company also has a joint venture and lithium-ion research and development (R&D) technology partner, Charge CCCV LLC (C4V). iM3NY has commercialized C4Vs patented cathode chemistry to produce green credentialed lithium-ion battery cells for use in both electric vehicles and battery energy storage systems. The firm also has a 100% interest in the Nachu Project, which is a large-scale natural flake graphite project in Tanzania.
📊 Share price
$0.16 AUD
Want more shares? Try these...
Acumentis Group Ltd. engages in the provision of valuation, research, and advisory services in relation to property and businesses. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-05. The firm provides commercial and residential valuations, research, and property advice to various homeowners, investors, developers, and lenders. The company offers property valuation, insurance valuation, and advisory services to clients, including banks and financial institutions, property developers, property trusts, government, lawyers, accountants, real estate agents and independent retailers. Its services include property valuation, property advisory, quantity surveying, acquisition and compensation, capital gains tax, family law and legal, fund forecasts, illicit substance screening, insurance valuation, litigation and legal advisory services, property buyers agencies, self-managed super fund (SMSF) property valuation, stamp duty assessments, tax depreciation schedules and tenant representation. The company serves property classes such as residential, commercial, rural, agribusiness and government portfolios.
📊 Share price